Ibrutinib - Pharmacyclics/Janssen

Drug Profile

Ibrutinib - Pharmacyclics/Janssen

Alternative Names: BTK Inhibitor PCI-32765; CRA-032765; IMBRUVICA; Imbruvica; ImBurvica; JNJ-54179060; PCI-32765

Latest Information Update: 13 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group
  • Developer Foundation GIMEMA; Genentech; Janssen; Janssen Biotech; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Northwestern University; OHSU Knight Cancer Institute; Pharmacyclics; Sheba Medical Center; Singapore General Hospital; Stanford University Medical Center; Thomas Jefferson University; University Hospital Muenster; University of California, Davis; University of Leeds
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antirheumatics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Graft-versus-host disease; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase II/III Pancreatic cancer
  • Phase II Acute myeloid leukaemia; B cell lymphoma; CNS cancer; Hairy cell leukaemia; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
  • Phase I Cancer; Myelodysplastic syndromes
  • Preclinical Colorectal cancer; Lymphoma
  • Discontinued Breast cancer; Rheumatoid arthritis; Seasonal allergic rhinitis

Most Recent Events

  • 29 Oct 2018 Janssen plans the real world setting EVIdeNCE trial for Chronic lymphocytic leukaemia in Italy (PO) (NCT03720561)
  • 17 Oct 2018 Preregistration for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in USA (PO)
  • 09 Oct 2018 Janssen Pharmaceutical terminates a phase I trial in B-cell lymphoma in Belgium and France as a result of decision from the French National Agency for Medicines and Health Products Safety due to due to veino occlusive disease (NCT02055924)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top